---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-285963"
form_type: "8-K/A"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2022-11-16T23:59:59+00:00"
generated_at: "2026-06-21T17:32:57.995199+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Imara sells PDE9 program (tovinontrine) to Cardurion for $35M upfront plus milestones

## Summary
- Upfront cash of $34.75M at closing plus $250K previously received; net proceeds ~$32.75M after ~$2M costs.
- Potential milestone payments: $10M for clinical proof-of-concept, $50M for regulatory/commercial events.
- Pro forma cash at Sep 30, 2022 rises to $82.2M; net loss for 9M 2022 falls from $30.7M to $13.0M.
- R&D expenses eliminated from $18.8M to $1.1M for 9M 2022 as sold asset costs are removed.
- Imara retains no further involvement in development or commercialization of the sold assets.

## SEC filing metadata
- accession: 0001193125-22-285963
- form_type: 8-K/A
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2022-11-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312522285963/0001193125-22-285963-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312522285963/d408792d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-285963
- JSON: https://secwatch.observer/filing/0001193125-22-285963.json
- Plain text: https://secwatch.observer/filing/0001193125-22-285963.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.